Short-term effectiveness and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis: results from a 16-week real-world multicenter retrospective study - il AD (Italian landscape atopic dermatitis).
Gargiulo L, Ibba L, Alfano A, Malagoli P, Amoruso F, Balato A, Barei F, Burroni AG, Caccavale S, Calzavara-Pinton P, Esposito M, Fargnoli MC, Ferrucci SM, Foti C, Girolomoni G, Gola M, Guanti MB, Gurioli C, Magliulo M, Maurelli M, Morrone P, Musumeci ML, Napolitano M, Ortoncelli M, Patruno C, Piraccini BM, Pezzolo E, Ribero S, Rossi M, Savoia P, Sciarrone C, Tirone B, Vaccino M, Veronese F, Costanzo A, Narcisi A.
Gargiulo L, et al. Among authors: foti c.
J Dermatolog Treat. 2024 Dec;35(1):2411855. doi: 10.1080/09546634.2024.2411855. Epub 2024 Oct 10.
J Dermatolog Treat. 2024.
PMID: 39389612
Free article.